Last reviewed · How we verify
20% Albumin
20% Albumin, marketed by the Institute of Liver and Biliary Sciences in India, holds a significant position in the albumin market. The drug's key composition patent is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | 20% Albumin |
|---|---|
| Sponsor | Institute of Liver and Biliary Sciences, India |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Study of DF1001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Recombinant Human Serum Albumin in Healthy Subjects (PHASE1)
- Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects (PHASE1)
- Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites (PHASE2, PHASE3)
- Phase II/III of Recombinant Human Serum Albumin (PHASE2, PHASE3)
- Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study (PHASE2)
- Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 20% Albumin CI brief — competitive landscape report
- 20% Albumin updates RSS · CI watch RSS
- Institute of Liver and Biliary Sciences, India portfolio CI